Leiomyosarcoma

The article says blood tests are used to diagnose #leiomyosarcoma. Not yet, but we have high hopes for ctDNA testing in #sarcoma, as noted at #ASCO23. (@SuzieSiegel)

This is a Facebook Live for patients & caregivers. The program will feature a panel of Fox Chase clinicians and researchers discussing promising treatments for #sarcoma and #leiomyosarcoma. Register here: https://t.co/SF49Z9qrBo. Today 6/13 at 6:30 ET. @jeffreyfarma (@Liferaftgroup)

What do you think? Will you consider temozolamide plus cabozantinib for your #leiomyosarcoma patients? Nice data from @AgulnikMd #ASCO23 (@DrLaraDavis)

From combination therapies to promising results in myxoid liposarcoma to a study of DNA repair gene in leiomyosarcomas, learn the latest sarcoma research presented by our experts at #ASCO23. https://t.co/jw5t2iBbHk @NeetaSomaiahMD @APConley77 @MNakazawa8 @ASCO #Sarcoma #EndCancer (@MDAndersonNews)

More data from rad onc group at @MDAndersonNews demonstrating outcomes of SSRS for #sarcoma spine Mets. #leiomyosarcoma represented 42% of pts. 1-yr LC rate 81% @ashleighg https://t.co/WSZ778KXxZ (@APConley77)

📢 Alert: POST-DOC position in #sarcoma at @MDAndersonNews ✅ Bioinformatics skills needed ✅ Interest in translational/preclinical studies ✅ Focus on #leiomyosarcoma Reach out to @NassifElise or @emilykeungMD for more #medtwitter #research #cancer (@FadiHaddad_MD)

Leiomyosarcoma? (@WidedAjouli)

Following Dr. Robin Jones' talk on #leiomyosarcomas, Dr. Peter Reichardt's talk on #liposarcomas, and Prof. Dr. Bernd Kasper's discussion on #desmoids, @JTrentMDPhD jokes that he has 10 minutes remaining to cover the other 172 subtypes. 😅 #SPAGN2023 (@sarcomapatients)

Abstracts of #lurbinectedin in the next ASCO conference #ASCO2023 #zepzelca #pharmamar #sclc #leiomyosarcoma (@pistoto2017)

This presentation by Dr. Michal on PLAG1-rearranged uterine leiomyosarcomas show heterogenous morphology which show lipomatous/osteochondromatous differentiation are observed to behave aggressively Further establishing how #molpath continues to enhance #gynpath! #uscap2023 (@anueru432)

@AnkitmanglaMD also spoke yesterday on the clinical trial for BA3011, a conditionally active biologic AXL-targeted antibody drug conjugate (CAB-AXL-ADC). Some #leiomyosarcoma express a lot of the AXL protein. #sarcoma https://t.co/KoPM0fdfvh (@SuzieSiegel)

Atypical spindle cell lesion favour DSFP. DD cutaneous leiomyosarcoma. Vimentin. (@debakeyforceps)

No. 1 - DDx: pleomorphis liposarc, UPS, pleomorphic leiomyosarcoma. IHC: MDM2, Desmin. No. 2 - DDx: IFP, IMT, GIST (not so convinced by the last). IHC: CD34, ALK, CD117, DOG1. Impressive cases as always!! Thank you for sharing! (@MirunaPopescu13)

Study led by @MDAndersonNews Dr. Timothy Yap. It’s a nuanced conclusion, and there is no tumor agnostic indication that will emerge here. Beyond “BRCA” cancers (#BreastCancer, #OvarianCancer, #PancreaticCancer & #ProstateCancer) the one surprise is uterine leiomyosarcoma. (@Aiims1742)

ctDNA in metastatic #leiomyosarcoma patients identified TP53 and RB mutations @NationalLMSF by @drjunaidarsh @PriscilaBCMD @GinaDAmatoMD1 (@JTrentMDPhD)

It does not come as a surprise given the long proven efficacy of checkpoint inhibitors in MSI-H tumors, but still important to have evidence of these in rare tumors with this ultra rare subset. #leiomyosarcoma #checkpoint (@AnkitmanglaMD)

RAD51 foci formation predicts DNA damage repair deficiency in #leiomyosarcoma. Awesome data presented by Sminu Bose from @ColumbiaMedic @DrCeSarcoma @JTrentMDPhD @SylvesterCancer @PriscilaBCMD @breelynwilkyMD @dileo_palma @GinaDAmatoMD1 (@AndreaEspejoMD)

Congrats Dr. Sam Bose on identifying lack of Rad51 and WES alterations associated with favorable outcome EFS in patients with uterine #leiomyosarcoma #ASCO22 #Sarcoma (@JTrentMDPhD)

On histo wd favour pleomorphic dermal sarcoma or leiomyosarcoma. Exclude melanoma, spindle cell SCC SOX10 S100 SMA Desmin AE1/3 CK5/6 CD10 (@girlscouter)

ALK as another tumor agnostic marker? MyPath pilot for alectinib. Disease control rate = 60% in ALK rearranged including PRs in colon and pancreatic and uterine leiomyosarcoma. No responses in ALK mutated or amplified (@Dr_R_Kurzrock)

Dr. Laura Madanat-Harjuoja & colleagues @DanaFarber will present "Circulating tumor DNA is associated w/ response & survival in patients w/ advanced #leiomyosarcoma" Tuesday at #AACR22. More ctDNA=worse prognosis. https://t.co/lJ6GCvPsBZ From SARC021. Also with @WTapMD. #sarcoma (@SuzieSiegel)

Diagnosing uterine PEComas is incredibly difficult! Especially if you always limit your spindle cell neoplasm ddx to ESS and Leiomyosarcoma. #USCAP2022 @ISGynP (@lendeschwartz)

Sign out now as: dermal atypical spindle cell proliferation, favor Atypical intradermal smooth muscle neoplasm ( cutaneous leiomyosarcoma), pending IHCs ( Sox10, CK5/6, SMA, Desmin and ERG) (@HENRYY_MD)

P53 mutation is the most common molecular aberration in #leiomyosarcoma by #ctDNA @drjunaidarsh @PriscilaBCMD @EmilyJonczak @GinaDAmatoMD1 @AndreaEspejoMD @SylvesterCancer https://t.co/eS07XZgyRB (@JTrentMDPhD)

There is an association between LOH and RB1 aberrations but not P53. The mechanism is not so clear in #Leiomyosarcoma? Is there a role for PARP inhibitors? #ctos2020 @ctosociety @nathanseligson (@JTrentMDPhD)

Erik A. Williams, MD @FoundationATCG #softtissuesarcoma CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1 https://t.co/yP82X2P4pX (@oncologytube)

Other differentials- Epithelioid leiomyosarcoma Dedifferentiated liposarcoma (can show variety of morphology) Like to add SMA , MDM2, CDK4 (@SumantaDas_7)

I'd love to see more on IGF-1R/mTOR in conventional #leiomyosarcoma. (@SuzieSiegel)